METHODS:
We subjected identically collected and processed serum samples from healthy volunteers and patients to automated polypeptide extraction on octadecylsilane-coated magnetic beads and separately on ZipTips before MALDI-TOF MS profiling at 2 centers. The 2 platforms were compared and case control profiling data analyzed to find altered MS peak intensities. We tested models built from training datasets for both methods for their ability to classify a blinded test set.
RESULTS:
Both profiling platforms had CVs of approximately 15% and could be applied for high-throughput analysis of clinical samples. The 2 methods generated overlapping peptide profiles, with some differences in peak intensity in different mass regions. In crossvalidation, models from training data gave diagnostic accuracies up to 87% for discriminating malignant ovarian cancer from healthy controls and up to 81% for discriminating malignant from benign samples. Diagnostic accuracies up to 71% (malignant vs healthy) and up to 65% (malignant vs benign) were obtained when the models were validated on the blinded test set.
CONCLUSIONS:
For ovarian cancer, altered MALDI-TOF MS peptide profiles alone cannot be used for accurate diagnoses.
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More than 204 000 new cases of ovarian cancer occur yearly (1 ) . The disease is associated with poor prognosis (2 ) , mainly due to late diagnosis attributable to lack of recognizable symptoms and lack of reliable screening methods. At presentation, Ͼ70% of patients exhibit disease spread beyond the pelvis [stage III, International Federation of Gynecology and Obstetrics (FIGO) 4 ]. The main diagnostic tests for symptomatic patients are transvaginal sonography and serum cancer antigen 125 (CA-125). However, CA-125 is also produced by other mesothelium-derived tissues and can be increased in benign conditions and other cancers. False negatives also occur because not all early-stage tumors produce CA-125 (3 ). Consequently, there are calls for better biomarkers for detecting and diagnosing early-stage ovarian cancer (4 ) .
The performance characteristics required of an ovarian cancer biomarker depend on the specific clinical use. Markers are currently used clinically along with imaging tests to differentiate benign pelvic masses from cancers before initial treatment in symptomatic women. For this indication, a marker would need to improve on or add to the performance of existing tests, which can achieve a diagnostic sensitivity of 85%-90% for detection of symptomatic ovarian cancer in combination with a specificity of 85%-90% for benign dis-ease (5 ) . A separate, more challenging clinical use would be screening for early detection of asymptomatic ovarian cancer. Large-scale trials using CA-125 and ultrasound can achieve 80%-90% diagnostic sensitivity for preclinical asymptomatic cancer (6 ) . The diagnostic specificity for screening asymptomatic postmenopausal women would need to be Ͼ98% so that when ultrasound is used as a second-line screen, the overall diagnostic specificity exceeds 99.6%.
Analysis of serum polypeptides holds promise for identifying novel cancer biomarkers, and various proteomic approaches have been used (7) (8) (9) . However, the serum proteome remains challenging, and few robust cancer biomarkers have been identified using proteomic profiling. Most candidates identified by mass spectrometry (MS)-based profiling are abundant acute-phase proteins (10, 11 ) and unlikely to be specific markers useful for accurate diagnosis (12 ) . Numerous studies have also highlighted alterations introduced during sample handling (13) (14) (15) (16) (17) (18) (19) . Differences in clotting time, transit time, temperature, storage, freeze-thaw cycles, and tube type all affect serum profiles, irrespective of biological variation. These changes are primarily driven by proteolysis, and it is therefore critical to process all samples identically. Concerns have also been raised over assay reproducibility and the robustness of class-discriminating algorithms used for proteomic biomarker discovery (12, 20, 21 ) .
MALDI-TOF MS and surface-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) MS provide high-throughput profiling, particularly when linked to automated sample processing. Although limited by mass range, MALDI-TOF MS has revealed the complexity of the low-mass serum and plasma proteomes (22 ) . Combined fractionation, MALDI-MS profiling, and tandem mass spectrometry (MS/MS) sequencing have identified Ͼ250 plasma peptides (23 ), unexpectedly derived from only approximately 20 common plasma proteins, suggesting extensive patterns of proteolytic cleavage. The cleavage patterns of some proteins have been associated with different disease conditions (24 ) . A high-throughput analysis of the serum carrier protein-bound peptidome (25 ) found that peptides could discriminate stage I ovarian cancers from healthy subjects with 93% diagnostic accuracy. Magnetic bead-based reversed phase extraction has also been combined with MALDI-TOF MS for serum peptide profiling (26 ) and later applied to find peptide peaks that could discriminate breast, bladder, and prostate cancer cases from healthy controls (27 ) . Identification of discriminatory peptides for each cancer by MS/MS revealed them to be ladders of related peptide fragments derived from abundant serum proteins. It was hypothesized that these are derived ex vivo during clotting, representing surrogate markers generated by alterations in serum concentrations or activities of the tumor-derived exopeptidases.
We investigated whether similar sets of peptides would be altered in samples from ovarian cancer cases and could be used to discriminate cases from controls or for differential diagnosis of malignant from benign ovarian neoplasm. (6, 28 ) . Serum samples from patients were collected before surgery for an ovarian neoplasm, and the diagnosis of malignant or benign ovarian neoplasm was confirmed by independent review of notes and histopathology reports. The healthy volunteers had no family history of ovarian cancer and no diagnosis of a cancer during follow-up. Serum samples (n ϭ 343) came from women diagnosed with malignant (n ϭ 70), borderline (n ϭ 11) (29 ), or benign (n ϭ 89) ovarian neoplasm and from healthy age-matched controls (n ϭ 173). Median and mean ages, histological subtypes, and sample numbers for each group are detailed in Table 1 . All samples were collected and processed essentially as described (30 ) .
Materials and Methods

SUBJECTS, SAMPLE COLLECTION, AND HANDLING
POLYPEPTIDE EXTRACTION AND MALDI-TOF MS-BASED
PROFILING
We processed and analyzed samples in 2 batches: batch 1 (n ϭ 129) comprised 22 malignant, 43 benign, and 64 healthy control samples, and batch 2 (n ϭ 214) comprised 48 malignant, 46 benign, 109 healthy, and 11 borderline/low malignant samples. Samples in each batch were randomized, thawed, aliquoted appropriately for each extraction method, and refrozen at Ϫ80°C before profiling.
C18-coated magnetic bead-based extraction and MS profiling.
We extracted triplicate serum samples using a previously reported reversed phase, batch extraction protocol (30 ) with some modifications (see Supple-mental File 1, which accompanies the online version of this article at www.clinchem.org/content/vol56/issue2). Briefly, we transferred an octadecylsilane (C18)-coated paramagnetic bead suspension (5 L; 50 g/L) to wells of 96-well plates containing 50 L serum, mixed the sample, and allowed it to stand for 1 min. We then magnetically pulled beads to the side and removed the supernatant. The beads were then washed 3 times in 0.1% trifluoroacetic acid (TFA) by pulling from sideto-side on magnets, collected by centrifugation, resuspended in 7 L elution solvent (50% acetonitrile, 0.1% TFA), and pulled to the side. We mixed the eluate with 35 L ␣-cyano-4-hydroxycinnamic acid (CHCA) matrix in 36%:56%:8% methanol:acetonitrile:water. Volumes of 1 L of the eluate/matrix mix were spotted in quadruplicate onto ground steel MALDI target plates and air-dried at room temperature. All steps were automated on a Genesis Freedom 200 liquid-handling work station (Tecan UK). For each target plate, 4 replicates of QC serum (Sigma-Aldrich; #S7023) were also extracted and spotted to monitor intra-and interassay variation. Spectral profiles were automatically acquired over a 700 -10 000 mass-to-charge (m/z) range in linear positive mode on a calibrated Ultraflex MALDI-TOF/TOF mass spectrometer (details in online Supplemental File 1). Briefly, each spectrum was the sum of 1000 laser shots delivered to different locations on the spot in 10 sets of 100 shots. We set evaluation parameters so that only spectra (of 100 shots) containing at least 1 peak with a resolving power Ͼ300 and a signal-to-noise ratio (S/N) Ͼ10 in a 700 -4000 m/z range were accumulated. Data were accepted if a sample had at least 3 of the 4 spotting replicates summing up 1000 shots in at least 2 of the 3 run replicates. Nine samples failed to yield reproducible spectra and were omitted from the analysis.
C18-ZipTip-based extraction and MS profiling.
We enriched serum polypeptides using reversed phase C18 ZipTips in an automated protocol, as described (31 ) . Briefly, we used an adapted CyBi™-Disk robot for processing. Aliquots of 5 L serum were acidified with 5 L of 2% TFA and then aspirated and dispensed 20 times through preconditioned ZipTips fitted to the robot head, followed by 3 washes with 10 L of 0.1% TFA. Polypeptides were eluted into a new plate by aspirating and dispensing (5 times) with 7 L of 50% acetonitrile, 0.1% TFA. We then mixed 3 L eluate with 27 L freshly prepared matrix solution (0.5 g/L CHCA in ethanol:acetone 2:1), immediately spotted 4 aliquots of 0.8 L onto a 600-m AnchorChip™ target plate (Bruker Daltonics), and allowed it to air-dry. Replicate samples of QC human serum were extracted and run alongside case control samples to monitor intra-and interassay variation. We obtained serum mass spectrometric profiles using an Ultraflex II MALDI-TOF/TOF mass spectrometer, but with slightly modified settings and procedure (see online Supplemental File 1). All samples were analyzed at least in triplicate on separate days. Data were accepted if the sample had at least 3 of the 4 spotting replicates summing up 1000 shots in at least 2 of the 3 run replicates per sample. All samples yielded reproducible spectra, although 1 sample could not be run due to insufficient starting material. A detailed standard operating protocol is provided in online Supplemental File 2.
DATA PROCESSING AND CLASSIFICATION
We processed raw MS profiling data from both methodsin parallel using the same steps and algorithms that were developed in-house (http://clrc.rhul.ac.uk/ projects/proteomic3.htm) (32 ) . Briefly, we averaged spectral data from replicate samples and performed a 5-fold data reduction (i.e., every fifth data point was taken). We then performed smoothing, baseline subtraction, normalization, and peak definition as described in online Supplemental File 1. We quantified peaks as the intensity at the local maximum and performed peak alignment to find common peaks (peak groups) using a 1500-ppm mass window. After processing, the peaks were clustered into 665 and 431 peak groups for the 2 datasets. Only peak groups appearing in Ͼ10% of samples were used for analysis. We used samples profiled in 2 batches to construct training and blinded test sets for classification. The training set from the C18 magnetic bead profiling (n ϭ 205; 42 malignant, 63 benign, and 100 healthy samples) contained all batch 1 samples and randomly selected batch 2 samples. The blinded test set (n ϭ 127; 39 malignant, 22 benign, and 66 healthy samples) contained the remaining samples from batch 2. The ZipTip training set (n ϭ 215) was similarly distributed, comprising 45 malignant, 64 benign, and 106 healthy samples. The blinded test set was the same for both methods. Borderline cases were considered malignant for training and classification. We constructed prediction models for 2 types of discrimination: malignant vs healthy and malignant vs benign. Different models using the weighted k-nearest neighbor algorithm (kNN), logical combinations of cutoff rules, and support vector machine (SVM) with various kernels were applied to subsets of peaks (usually a small number). We performed crossvalidation by randomizing the sample labels in 1000 iterations and calculating P values (Monte Carlo method) for the randomly permutated and correctly labeled samples. The models performing best on the training set (all weighted kNN models) were then validated on the blinded test set.
PEAK IDENTIFICATION BY Q-TOF MS/MS
We obtained peak identifications by analyzing samples on a Q-TOF Premier mass spectrometer (Waters) either in MALDI mode, using a similar MALDI sample preparation to that described above with slight modifications to account for the different type of target used, or in the electrospray ionization (ESI) mode. In the latter case, samples were fractionated by C18-based reversed-phase HPLC before ESI analysis. Fractions (Ͼ60 in total) were split in 2, and 1 aliquot was digested with trypsin to facilitate identification of the major protein components in each fraction. Where possible, informative MS/MS sequence data of the other nondigested fraction was used for identification, using the protein identifications from the digested fraction to provide a limited set of theoretical peptide masses for comparison. Hits with mass accuracy Ͻ75 ppm were further evaluated by comparison of experimental fragment ions with theoretical fragmentation products. In the cases where no MS/MS data from the undigested fractions were available, we used comparison with already identified fragments and known protein structural information for putative identifications.
Results
COMPARISON OF MALDI-TOF PROFILING METHODS USING
DynalC18 BEAD AND ZipTip EXTRACTION
We developed 2 semiautomated serum peptide profiling methods based on extraction with C18-coated magnetic beads and C18 ZipTips, respectively. Assay performance was assessed for each method within and across robotic runs using a QC serum sample processed and spotted multiple times with test samples. The C18 magnetic bead-based extraction method gave mean interassay CVs of 15.7% (7.2%) and 13.9% (7.6%) in batches 1 and 2, respectively, when all detected peak intensities were considered. The ZipTip method had interassay CVs of 15.0% (7.5%) and 13.7% (8.3%). Fig.  1 shows aligned QC spectra as heat maps for both methods, containing approximately 200 peaks/spectra (m/z 700 -10 000; S/N Ͼ3), with considerable overlap in peak profiles given by the 2 extraction methods. There were some differences in intensity, likely reflecting the differential binding capacities of the 2 resin types used. An automated spectral quality filter was applied during MS data acquisition (see "Materials and Methods"), and both methods performed well in terms of sample dropout; spectra satisfying the filtering criteria were obtained for 334 of 343 samples and 342 of 342 samples for the magnetic bead and ZipTip method, re-spectively. Comparison of spectral profiles of clinical samples again revealed overlapping but distinct profiles for the 2 methods ( Fig. 2A-E) . The ZipTip method tended to generate higher-intensity peaks in the range 1200 -1700 m/z, whereas the magnetic bead-based method gave more uniform intensities across the entire mass range. Profiles of clinical samples and QC samples were distinct, presumably reflecting the difference in origin and different handling conditions used in its preparation.
Spectral processing of all clinical samples revealed 665 and 431 aligned peak groups in total for the UCL and University of Reading (UoR) datasets, respectively. For further analysis, only peak groups appearing in Ͼ10% of samples were considered for analysis, reducing peak numbers to 132 (magnetic bead dataset) and 108 (ZipTip dataset), mostly through removal of lowintensity peaks. Online Supplemental File 3 shows the filtered peak lists. We next calculated Mann-Whitney U-test P values, checking the hypothesis that healthy samples from the training set drawn from batch 1 and healthy samples from the training set drawn from batch 2 came from the same distribution. Peaks with Bonferroni-adjusted P values Ͼ0.01 (referred to as "unstable peaks," online Supplemental File 3) were eliminated. The motivation behind this was to produce a list of peaks that were stable with respect to the healthy control samples. As a result, 36 and 20 unstable peaks were excluded from the 2 datasets, reducing the peak sets to 96 (magnetic bead) and 88 (ZipTip).
CLASSIFICATION PERFORMANCE USING MS PEAKS
We generated multiple models from the training set using a variety of learning methods including weighted kNN, SVM, and simple cutoff rules. We found that using pairs of peaks gave the best performances; increasing the number of peaks did not provide stable or reproducible results as a consequence of over-fitting (see online Supplemental File 1). The use of peak area vs peak intensity gave no appreciable difference in performance. Of the classification methods tested, the weighted kNN models performed best on crossvalidation. We found that various pairs of peaks performed reasonably well on the 2 training sets for discriminating healthy and malignant samples, with accuracies of 80%-87.1% for the magnetic bead set and 63.45-86.6% for the ZipTip set ( Table 2) . However, these models performed less well when validated on the blinded test set; the best performance was 63.9% diagnostic accuracy for the magnetic bead dataset and 73.3% for the ZipTip dataset. Notably, there was no overlap in peaks used from the 2 datasets for discriminating healthy and malignant samples.
Performance on the training sets for classification of malignant vs benign samples was 66.7%-81.9% accuracy for the UCL data and 66.3%-79.2% for the UoR data (Table 3 ). These models performed only moderately well on the validation set, with highest accuracies of 62.3% and 65.6% for the UCL and UoR datasets, respectively. Several peaks used for discriminating malignant from benign cases were likely the same peptides (m/z 3509.6/3507.3, m/z 4056.8/4053.8, and m/z 4093.4/4091.1). Additionally, several peaks were commonly used for the malignant-vs-healthy and malignant-vs-benign classifications for each dataset. Overall, it appeared that the data contained in the high- 
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throughput MALDI-TOF MS profiles using the methodologies described did not provide accurate diagnosis of ovarian cancer.
IDENTIFICATION OF PEAKS
To identify the peptides observed in the MS profiles as possible biomarkers of ovarian cancer and to compare our methods with previous work (27, 33 ) , we attempted to identify as many of the detected peaks as possible. Briefly, Ͼ50 peptides were identified with high confidence, representing proteolytic products from Ͻ20 different proteins (data not shown). From this analysis, we were able to identify peaks of the best models used in discriminating benign and malignant samples, but few in the healthy-vs-malignant classification (Tables 2 and 3 
Discussion
We applied 2 high-throughput polypeptide extraction methods linked to automated MALDI-TOF MS profiling to a set of identically collected and processed serum samples from healthy controls and women diagnosed with ovarian cancer and benign ovarian neoplasm. Our main aim was to identify putative peptide biomarkers for detecting ovarian cancer and for differential diagnosis of malignant and benign cases. We also wanted to compare results with previous studies, where a similar strategy was used to identify serum peptide markers of other cancer types, hypothesized to be generated by the actions of tumor-specific exoprotease activities (27, 33 ) . Both the ZipTip and magnetic bead extraction linked to MS profiling were successfully automated, were reproducible when tested on a QC sample, and had low sample dropout rates. The reproducibility (CVs of approximately 15%) of the 2 assays considered all matched peaks across the spectra with signal-to- noise ratios Ͼ3, rather than a few abundant (and often stable) peaks, and was higher than what has been reported for MALDI-based serum profiling. The methods generated highly overlapping spectral profiles that were consistent with those previously reported, and a number of the same peptidase-generated serum protein fragments were identified by MS/MS. In particular, all identified peptide peaks, apart from m/z 1547 and 5913, were previously reported to be statistically significant in discriminating cancer cases from controls (27 ) . Despite the proven reproducibility of the profiling methods used, and the fact that samples were identically handled according to a previously optimized protocol (15, 30 ) , the peak-intensity information obtained could not be used for high-accuracy classification of malignant and benign cases in our validation set. The performance of pairs of peaks in kNN models fell below that of serum CA-125, for which overall diagnostic sensitivities of approximately 80% and specificities Ͼ95% have been reported, particularly when monitored over time in the same individuals (4, 34 ) . Thus, it appears that in the case of ovarian cancer, differential exoprotease activities are not present in the serum to confer tumor-specific peptidome patterns useful for detection and diagnosis. The reasons for this are unclear, but could represent the different molecular etiology of ovarian cancer and its subtypes, vs the prostate, breast, bladder, and thyroid cancer used in previous studies (27, 33 ) . This difference may represent the lack of expression of such exoproteases in ovarian cancer cells, their preferential inhibition, or reduced secretion/shedding into the bloodstream.
Whereas earlier studies have reported that MSbased serum profiling could be used to accurately distinguish cancer from healthy or benign cases (35, 36 ) , the observed differences in MS profiles were due to artifacts of sample processing and selection (37, 38 ) . Standard operating procedures for sample collection and handling (39 ) must be implemented. The sample handling procedures implemented here were tightly controlled to avoid such biases, further supporting the notion that diagnostic biomarkers for ovarian cancer are not detectable in the low-mass proteome of serum using the applied MALDI-TOF MS profiling methods. Thus, although high-throughput MALDI-TOF MS profiling of the serum peptidome using the methods described does provide some information for ovarian cancer detection and diagnosis, the markers identified would be unsuitable for clinical use on their own.
